在一般人群中服从性和对冠心病的保护:爱丁堡动脉研究
M C Whiteman1, I J Deary, A J Lee
1Wolfson Unit for the Prevention of Peripheral Vascular Diseases, Department of Public Health Sciences, University of Edinburgh, UK.
Lancet (London, England)
|August 23, 1997
概括
顺服可能会防止非致命的心肌梗塞,特别是在女性中. 这种人格特质似乎可以降低心脏病发作的风险,因此需要进一步研究其在心血管健康中的复杂作用.
科学领域:
- 心脏病学 心脏病学
- 心理学 心理学 心理学
- 流行病学 流行病学
背景情况:
- 敌意和愤怒与冠心病 (CHD) 风险增加有关.
- 有限的研究存在于其他人格特征,如顺从,以及它们与CHD的关联.
- 这项研究研究了服从性作为未来冠状动脉疾病风险的独立预测因素.
研究的目的:
- 确定服从的个性特征是否与一般人群未来冠心病 (CHD) 风险有关.
- 评估服从和心血管事件之间的独立关系,而不是敌意.
- 探索潜在的性别差异在服从性和CHD风险之间的关联.
主要方法:
- 爱丁堡动脉研究是一项队列研究,涉及809名55-74岁的男性和783名女性.
- 在1988年基线,使用贝德福德-福尔德斯人格偏差量表来评估人格.
- 参与者在5年内进行了心血管事件的跟踪,包括心肌梗塞和胸痛.
主要成果:
- 与经历过心肌梗塞的人相比,在没有致命心肌梗塞的个人中观察到更高的平均顺服度得分 (p=0.023在男性中,p=0.002在女性中).
- 服从性与女性非致命心肌梗塞风险降低独立相关 (RR0.59,95% CI 0.40-0.85).
- 服从性标准偏差增加与女性心肌梗塞总发病风险降低有关 (RR 0.69,95% CI 0.27-0.96).
结论:
- 服从的个性特征可能会对非致命的心肌梗塞产生保护作用,特别是在女性身上.
- 需要进一步的研究才能充分理解人格特征与冠状动脉疾病发展之间的复杂相互作用.
- 服从性是评估心血管疾病风险的一个潜在的新因素.
相关概念视频
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...